The blood pressure medication angiotensin - converting enzyme inhibitors (ACEIs) appear to reduce major cardiovascular events and
death, as well
death from all other causes, in patients with diabetes, while angiotensin II
receptor blockers (ARBs) appear to have no
such effect on those outcomes.
The Lauffenburger research group focuses on elucidating important aspects of
receptor - mediated regulation of mammalian blood and tissue cell behavioral functions
such as proliferation, adhesion, migration, differentiation, and
death.